When it comes to innovation, midmarket firms frequently lead the way. Take the budding field of personalized medicine, where forward-looking organizations like New Jersey's Coriell Institute are laying groundwork for a new generation of drugs that will be uniquely tailored to each individual patient. A small nonprofit with fewer than 200 employees, Coriell is leveraging IBM technology to create a next-generation "DNA bank," a critical tool for constructing tomorrow's "smart" medicines and treatments